Awad was recruited in 2010 to lead the Neurovascular Surgery Program at the University of Chicago Medicine, and is currently tenured in the Biological Sciences Division. He is the John Harper Seeley Professor of Neurological Sciences and Professor of Neurological Surgery, Neurology, the Grossman Institute of Neuroscience, Quantitative Biology and Human Behavior, and the (PhD granting) Committee on Neurobiology. He is a Senior Faculty Scholar at the Bucksbaum Institute for Clinical Excellence and directs the Safadi Program of Excellence in Clinical and Translational Neurosciences. Dr Awad is active in numerous professional and learned societies. He has served on the Executive Committee of the American Stroke Association, and on the Board of Governors of the American College of Surgeons. He was the Chairman of the Joint Cerebrovascular Section of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons, he has directed the Annual Course on Research Update in Neuroscience for Neurosurgeons, and he served as the 51st President of the Congress of Neurological Surgeons. Dr Awad is the Founding past-President of the World Association of Lebanese Neurosurgeons, and the Founding Chairman of Scientific Advisory Board of the patient advocacy group Angioma Alliance.
Dr Awad has authored over 350 scientific papers and book chapters, and edited twelve books dealing with cerebrovascular surgery and other aspects of neurological surgery. He has presented over 500 papers and lectures at major meetings and symposia, has been a visiting professor at numerous institutions in the United States and abroad, was recognized among America’s Best Doctors, Best Teachers, and is the recipient of the Bucy Award for Excellence in Neurosurgical Education, the Arnold Award for Mentoring at Pritzker School of Medicine, and numerous other honors. Dr Awad has made numerous scientific contributions including the characterization of subcortical ischemic lesions in the aged, advances in the understanding of the natural history and biologic behavior of vascular malformations of the brain, numerous technical advances in neurovascular and epilepsy surgery, and is a recognized expert in the treatment of neurovascular disease, hemorrhagic stroke and neurosurgical critical care. His research has been cited by other researchers more than 79,000 times (H-index 91). Current research focuses on molecular mechanisms, biomarkers and therapeutic targets in cavernous angiomas (cerebral vascular malformations), the pathobiology of brain hemorrhage, and minimally invasive techniques for treating hemorrhagic stroke.
Dr. Awad's research has been funded continuously from the National Institutes of Health since 1998, including a prestigious midcareer development grant in patient-oriented research (2000-2005), and current active R01, P01 and U01 funding through 2025. From 2016 to 2020, he served on the United States National Advisory Council for Neurological Disorders and Stroke. In 2019, he was elected to the Association of American Physicians.
www.issamawad.com
www.uchicagomedicine.org/ccm
www.uchicagomedicine.org/hht
http://safadiprogram.uchicago.edu
Barrow Neurological Institute
AZ
Neurovascular surgery fellowship
Royal Infirmary of Edinburgh
Scotland
Neurotraumatology fellowship
Cleveland Clinic
OH
Neurosurgical residency
Loma Linda University
CA
MD
Loma Linda University
CA
MS
Multidisciplinary coordinated care of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease).
Multidisciplinary coordinated care of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease). Vasc Med. 2023 Apr; 28(2):153-165.
PMID: 36890671
Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma.
Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma. Commun Med (Lond). 2023 Mar 03; 3(1):35.
PMID: 36869161
?1 integrin monoclonal antibody treatment ameliorates cerebral cavernous malformations.
?1 integrin monoclonal antibody treatment ameliorates cerebral cavernous malformations. FASEB J. 2022 Dec; 36(12):e22629.
PMID: 36349990
Credulity of exploratory trials for cerebral cavernous malformations.
Credulity of exploratory trials for cerebral cavernous malformations. Lancet Neurol. 2023 01; 22(1):2-3.
PMID: 36403581
Evidence-based interconversion of the Glasgow Outcome and modified Rankin scales: pitfalls and best practices.
Evidence-based interconversion of the Glasgow Outcome and modified Rankin scales: pitfalls and best practices. J Stroke Cerebrovasc Dis. 2022 Dec; 31(12):106845.
PMID: 36309002
One-Year Outcome Trajectories and Factors Associated with Functional Recovery Among Survivors of Intracerebral and Intraventricular Hemorrhage With Initial Severe Disability.
One-Year Outcome Trajectories and Factors Associated with Functional Recovery Among Survivors of Intracerebral and Intraventricular Hemorrhage With Initial Severe Disability. JAMA Neurol. 2022 09 01; 79(9):856-868.
PMID: 35877105
Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease.
Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease. Transl Stroke Res. 2022 Jun 17.
PMID: 35715588
Association of Intraventricular Fibrinolysis With Clinical Outcomes in Intracerebral Hemorrhage: An Individual Participant Data Meta-Analysis.
Association of Intraventricular Fibrinolysis With Clinical Outcomes in Intracerebral Hemorrhage: An Individual Participant Data Meta-Analysis. Stroke. 2022 09; 53(9):2876-2886.
PMID: 35521958
Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans.
Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans. ACS Pharmacol Transl Sci. 2022 May 13; 5(5):266-277.
PMID: 35592432
Bayesian deep learning outperforms clinical trial estimators of intracerebral and intraventricular hemorrhage volume.
Bayesian deep learning outperforms clinical trial estimators of intracerebral and intraventricular hemorrhage volume. J Neuroimaging. 2022 09; 32(5):968-976.
PMID: 35434846